After Neoprobe (NYSE Amex:NEOP) sold off its top revenue-producing asset (along with its name) to transform itself into a pure-play radiopharmaceutical company, it had to find itself a new brand.Now, the company is on the verge of announcing that brand, CEO Mark Pykett said in the Dublin, Ohio company’s third-quarter earnings release.“In the coming weeks, [...]

Life science current events this week include Neoprobe gets Lymphoseek’s New Drug Application accepted by FDA but hedge fund critic still predicts it will not win approval, and Cleveland Clinic’s wellness chief Michael Roizen’s new venture.

After remaining silent on Neoprobe (NYSE Amex:NEOP) the last few months, the cancer diagnostics company’s most outspoken critic and short seller has found himself back in the spotlight after the FDA accepted for review a drug application from the company.And that critic — Martin Shkreli of New York hedge fund MSMB Capital — is still [...]

The U.S. Food and Drug Administration has accepted cancer diagnostics company Neoprobe‘s (NYSE Amex:NEOP) New Drug Application for its radiopharmaceutical Lymphoseek.FDA acceptance of the Lymphoseek NDA is an important milestone for the Dublin, Ohio, company and provides vindication over a once-vocal hedge fund manager critic who raised questions about the design of the drug’s clinical [...]

Two current and one former Neoprobe (NYSE Amex:NEOP) executive plan to begin unloading shares of the cancer diagnostics company after the U.S. Food and Drug Administration accepts an application associated with its radiopharmaceutical Lymphoseek.CFO Brent Larson could sell up to 12 percent of his equity in the company, while Roger Brown, vice president of regulatory [...]

Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) said it had gained clarity around the chemistry and manufacturing of its investigational colorectal cancer detection drug after a meeting with European regulators.Most significantly to Neoprobe, the meeting confirmed the company’s opportunity to develop a humanized antibody rather than a mouse-based antibody in its clinical development of RIGScan, a [...]

In a deal that marks its transformation to a pure-play radiopharmaceutical company, Neoprobe (NYSE Amex:NEOP) has completed the sale of its radiation detection business to Devicor Medical Products.The deal’s value could reach $50 million for Dublin, Ohio-based Neoprobe — $30 million up front and $20 million in royalties if Devicor’s sales of the acquired products [...]

Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) is continuing to enroll patients in a phase 3 head and neck cancer clinical trial of its radiopharmaceutical Lymphoseek.The trial is aimed at expanding Lymphoseek’s label to cover procedures known as sentinel lymph node biopsies, CEO Mark Pykett said in a conference call with investors. The sentinel lymph node [...]

Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has filed a New Drug Application for its radiopharmaceutical Lymphoseek.The filing is a key step for the company and has been a long time coming. If the U.S. Food and Drug Administration approves the application, Neoprobe could begin selling the drug, which would represent a huge milestone for the [...]

Figuring Neoprobe‘s (NYSE Amex:NEOP) stock price has fallen far enough, the hedge fund manager who drew attention for criticizing the company has called off his recommendation to short its shares.Martin Shkreli, CEO of New York-based hedge fund MSMB Capital, said that with Neoprobe hovering slightly above $2, he “cannot in good faith” recommend maintaining a [...]